[go: up one dir, main page]

US20020091113A1 - Treatment of septic shock - Google Patents

Treatment of septic shock Download PDF

Info

Publication number
US20020091113A1
US20020091113A1 US09/971,079 US97107901A US2002091113A1 US 20020091113 A1 US20020091113 A1 US 20020091113A1 US 97107901 A US97107901 A US 97107901A US 2002091113 A1 US2002091113 A1 US 2002091113A1
Authority
US
United States
Prior art keywords
transition metal
iron
manganese
metal complex
deferoxamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/971,079
Inventor
Wieslaw Kazmierski
Luis Molina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molichem Medicines Inc
Original Assignee
Molichem Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molichem Medicines Inc filed Critical Molichem Medicines Inc
Priority to US09/971,079 priority Critical patent/US20020091113A1/en
Publication of US20020091113A1 publication Critical patent/US20020091113A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to the use of transition metal complexes for the treatment of septic shock, and in particular the hypotension associated therewith.
  • Garavilla et al. disclose deferoxamine-manganese complexes which are superoxide dismutase mimics and improve survival following haemorrhagic and endotoxic shock.
  • Sanan et al disclose the use of desferrioxamine mesylate to increase the survival rate of anaesthetised dogs subjected to haemorrhagic shock
  • U.S. Pat. No. 5,296,466 discloses the use of an iron hemoprotein for the treatment of systemic hypotension or other pathogenic syndromes induced by inappropriate NO production.
  • transition metal complex increases the survival rate in mice subjected to endotoxin induced septic shock.
  • transition metal complex will be understood by one skilled in the art as a transition metal which is linked to one or more chelating agents (ligands). All transition metal complexes other than deferoxamine-manganese, hemin, diethyldithiocaramic acid complexes and iron hemoproteins are included.
  • the present invention provides the use of a transition metal complex as hereinbefore defined in the manufacture of a medicament for the treatment of septic shock and in particular the hypotension associated therewith.
  • a method of treating septic shock and in particular the hypotension associated therewith comprising administering to a mammal in need thereof an effective amount of a transition metal complex as hereinbefore defined.
  • Suitable transition metals include iron, copper, silver, zinc, manganese and nickel. Iron is a particularly preferred transition metal.
  • Suitable chelating agents include those that are coordinated to the transition metal through one or more nitrogen atoms which may be contained in a polycyclic ring system or as a substituent in an alkylene chain: through an O ⁇ or S ⁇ anion; or by virtue of a pair of electrons.
  • Preferred ligands include:
  • Q and Q′ may be the same or different and are independently a C 2-10 alkyiene chain. Most preferably Q is a C 5 -alkylene chain and Q′ is a C 2 -alkylene chain.
  • R 16 is C 1-6 alkyl chain optionally substituted by a group CO 2 H or a group NR 17 R 18 wherein R 17 and R 18 are independently selected from (III or C 1-4 alkyl optionally substituted by a group CO 2 H
  • n 1 to 6, preferably 2.
  • R is a C 1-6 sulphonic acid or carboxylic acid group.
  • ligands hereinbefore described are shown in their neutral form, although they can also exist in ionic form e.g. as a cation or anion.
  • the exact stoichiometry of metal to ligand depends on their electronic properties, e.g. charge and the number of coordination centres.
  • the invention is intended to include all possible stoichriometric alternatives.
  • Specifically preferred complexes include:
  • Most preferred complexes are ferrioxamine B and diethylenetriaminepentaacetic acid Iron (III).
  • the transition metal complexes of the present invention may act by scavenging nitric oxide (NO) in the body. Therefore, in addition to being of use in the treatment of septic shock the transition metal complexes may also be of use in the treatment of other conditions caused by pathological NO production. Accordingly the present invention further provides the use of a transition metal complex in the manufacture of a medicament for the treatment of conditions caused by pathological NO production.
  • NO nitric oxide
  • a transition metal complex of the present invention may be of use during therapy with cytokines such as TNF, IL-1 and IL-2 or therapy with cytokine-inducing agents, for example 5,6-dimethyl xanthenone acetic acid; as an adjuvant to short term immunosuppression in transplant therapy; in patients suffering from inflammatory conditions in which an excess of NO contributes to the pathophysiology of the condition, for example adult respiratory distress syndrome and myocarditis; and in autoimmune and/or inflammatory conditions, such as arthritis and rheumatoid arthritis.
  • cytokines such as TNF, IL-1 and IL-2
  • cytokine-inducing agents for example 5,6-dimethyl xanthenone acetic acid
  • transition metal complexes may be of use include cerebral ischemia, CNS trauma, epilepsy, AIDS dementia, chronic pain, schizophrenia and conditions in which non-adrenegic, non-cholinergic nerve may be implicated such as priapism, obesity and hyperphazia.
  • transition metal complexes of the present invention may be administered alone or in conjunction with another therapeutic agent, for example a NO synthase inhibitor such as an arginine derivative eg L-NMMA. Accordingly, a vet further aspect of the invention provides the use of a transition metal complex in conjunction with a NO synthase inhibitor in the manufacture of a medicament for the treatment of conditions caused by pathological NO production.
  • a NO synthase inhibitor such as an arginine derivative eg L-NMMA.
  • a further aspect of the present invention provides a transition metal complex as hereinbefore defined other than ferrioxamine B for use in medicine.
  • the transition metal complexes Whilst it may be possible for the transition metal complexes to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation.
  • the present invention provides a pharmaceutical formulation comprising a transition metal complex as hereinbefore defined other than ferrioxamine B together with one or more pharmaceutically acceptable carriers therefor and optionally one or more other therapeutic ingredients.
  • the carrier(s) must be “acceotable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. Most suitably, the formulation is suitable for oral or parenteral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy All methods include the step of bringing into association the transition metal complex (“active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
  • Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, saline, water-for-injection, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.
  • Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
  • Preferred unit dosage formulations are those containing an effective dose, as hereinbelow recited, or an appropriate fraction thereof, of the active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
  • the transition metal complexes of the invention may be administered orally or via injection at a dose of from 0.1 to 100 mg/kg per day, preferably 1 to 50 mg/kg per day.
  • a dose of from 0.1 to 100 mg/kg per day preferably 1 to 50 mg/kg per day.
  • this will normally be in the form of an intravenous bolus or by infusion, preferably the latter.
  • the dose range for adult humans is generally from 70 mg to 2.5 g/day and preferably 150 mg to 2 g/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.
  • the dose of the transition metal complexes vary according to the potency and the dose at which adverse pharmacological effects become evident. The man skilled in the art will take these factors into account when determining the dose of compound to be administered.
  • Ferrioxamine B (deferoxamine-Fe(III) was synthesized by complexation reaction of Fe(III) salt (specifically FeNH 4 (SO 4 ) 2 .12H 2 O) with deferoxamine mesylate.
  • Deferoxamine mesylate is N-[5-[3-[(5-amino-pentyl)hvdroxycarbamoyi]proplonoamido]pentyl]-3-[[5-(N-hydroxyactemido)-pentyl]carbamoyl]propionohydroxamic acid monomethanesulfonate(salt).
  • the complex was then purified on a reverse phase HPLC.
  • Deferoxamine mesylate was from Ciba-Geigy and ferric pyridoxal isonicotinoyl hydrazone and was obtained from Polysciences, Inc. (Warrington, Pa.).
  • the Mouse Acute Septic-Shock model is used to test compounds for their capacity to ameliorate endotoxin-induced fulminate septic shock.
  • mice Male CD-I mice 25-30 g (Charles River) were injected i.v. with 100 ⁇ g killed C. parvum (Coparvax: Burroughs Weffcome. RTP. NC). Seven to ten days later the mice were injected i.v. with 20 ⁇ g. E. coli 026 B6 lipopolysaccharide in the presence of the analgesic butorphenol tartrate (150 ⁇ g per mouse) The drugs were dissolved or suspended in saline for intravenous or oral dosing 2 hours before and at the time of endotoxin injection. Mice were monitored over the next 7 hours and at 24-48 hours for survival. The results of the compounds tested are given in Table 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Removal Of Specific Substances (AREA)
  • Pyrane Compounds (AREA)
  • Treatment Of Sludge (AREA)
  • Registering, Tensioning, Guiding Webs, And Rollers Therefor (AREA)
  • Gas Separation By Absorption (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

The use of transition metal complexes in the treatment of septic shock in particular the hypotension associated therewith and pharmaceutical formulations comprising such complexes are disclosed. The use of such transition metal complexes in the treatment of other conditions caused by pathological NO production are also disclosed.

Description

  • The present invention relates to the use of transition metal complexes for the treatment of septic shock, and in particular the hypotension associated therewith. [0001]
  • Garavilla et al. (Drug. Dev. Res. 25 139-148, (1992)) disclose deferoxamine-manganese complexes which are superoxide dismutase mimics and improve survival following haemorrhagic and endotoxic shock. Sanan et al (Pharmacos 28:103-105, (1985)) disclose the use of desferrioxamine mesylate to increase the survival rate of anaesthetised dogs subjected to haemorrhagic shock U.S. Pat. No. 5,296,466 discloses the use of an iron hemoprotein for the treatment of systemic hypotension or other pathogenic syndromes induced by inappropriate NO production. [0002]
  • It has now been found hat transition metal complexes increase the survival rate in mice subjected to endotoxin induced septic shock. The term ‘transition metal complex’ will be understood by one skilled in the art as a transition metal which is linked to one or more chelating agents (ligands). All transition metal complexes other than deferoxamine-manganese, hemin, diethyldithiocaramic acid complexes and iron hemoproteins are included. [0003]
  • Accordingly the present invention provides the use of a transition metal complex as hereinbefore defined in the manufacture of a medicament for the treatment of septic shock and in particular the hypotension associated therewith. Alternatively, there is provided a method of treating septic shock and in particular the hypotension associated therewith comprising administering to a mammal in need thereof an effective amount of a transition metal complex as hereinbefore defined. [0004]
  • Suitable transition metals include iron, copper, silver, zinc, manganese and nickel. Iron is a particularly preferred transition metal. [0005]
  • Suitable chelating agents include those that are coordinated to the transition metal through one or more nitrogen atoms which may be contained in a polycyclic ring system or as a substituent in an alkylene chain: through an O[0006] − or S− anion; or by virtue of a pair of electrons.
  • Preferred ligands include: [0007]
  • those of formula (I) [0008]
    Figure US20020091113A1-20020711-C00001
  • wherein Q and Q′ may be the same or different and are independently a C[0009] 2-10 alkyiene chain. Most preferably Q is a C5-alkylene chain and Q′ is a C2-alkylene chain.
  • (ii) those of formula (II) [0010]
    Figure US20020091113A1-20020711-C00002
  • (iii) those of formula (III) [0011]
    Figure US20020091113A1-20020711-C00003
  • (iv) those of formula (IV) [0012]
    Figure US20020091113A1-20020711-C00004
  • wherein R[0013] 16 is C1-6 alkyl chain optionally substituted by a group CO2H or a group NR17R18 wherein R17 and R18 are independently selected from (III or C1-4 alkyl optionally substituted by a group CO2H
  • (v) those of formula (V) [0014]
    Figure US20020091113A1-20020711-C00005
  • (vi) those of formula (VI) [0015]
    Figure US20020091113A1-20020711-C00006
  • (vii) those of formula (VII) [0016]
    Figure US20020091113A1-20020711-C00007
  • (viii) those of formula (VIII) [0017]
    Figure US20020091113A1-20020711-C00008
  • wherein n is 1 to 6, preferably 2. [0018]
  • (ix) those of formula (IX) [0019]
    Figure US20020091113A1-20020711-C00009
  • wherein R is a C[0020] 1-6 sulphonic acid or carboxylic acid group.
  • (x) those of formula (X) [0021]
    Figure US20020091113A1-20020711-C00010
  • (xi) those of formula [0022]
  • NH3
  • The ligands hereinbefore described are shown in their neutral form, although they can also exist in ionic form e.g. as a cation or anion. The exact stoichiometry of metal to ligand depends on their electronic properties, e.g. charge and the number of coordination centres. The invention is intended to include all possible stoichriometric alternatives. [0023]
  • Specifically preferred complexes include: [0024]
  • Ferrioxamine B [0025]
  • Ferric Pyridoxal Isonicotinoyl Hydrazone [0026]
  • Tris (acetylacetonato)manganese (III) [0027]
  • Iron (III) citrate [0028]
  • Diethylenetriaminepentaacetic acid Iron (III) [0029]
  • Ethylenediaminetetraacetic acid Iron (III) [0030]
  • Ferrous gluconate [0031]
  • 1,1′-ferrocenedimethanol [0032]
  • Ethyl α-acetyl-4-(methoxycarbonyl)benzoylacerate, Copper (II) [0033]
  • Tris (ethylenediamine) nickel (II) sulfate [0034]
  • Hexaaminenickel (II) Chloride [0035]
  • Bathopheneanthroline disulphonic acid [0036]
  • Most preferred complexes are ferrioxamine B and diethylenetriaminepentaacetic acid Iron (III). [0037]
  • It is believed that the transition metal complexes of the present invention may act by scavenging nitric oxide (NO) in the body. Therefore, in addition to being of use in the treatment of septic shock the transition metal complexes may also be of use in the treatment of other conditions caused by pathological NO production. Accordingly the present invention further provides the use of a transition metal complex in the manufacture of a medicament for the treatment of conditions caused by pathological NO production. [0038]
  • A transition metal complex of the present invention may be of use during therapy with cytokines such as TNF, IL-1 and IL-2 or therapy with cytokine-inducing agents, for example 5,6-dimethyl xanthenone acetic acid; as an adjuvant to short term immunosuppression in transplant therapy; in patients suffering from inflammatory conditions in which an excess of NO contributes to the pathophysiology of the condition, for example adult respiratory distress syndrome and myocarditis; and in autoimmune and/or inflammatory conditions, such as arthritis and rheumatoid arthritis. Other conditions in which such transition metal complexes may be of use include cerebral ischemia, CNS trauma, epilepsy, AIDS dementia, chronic pain, schizophrenia and conditions in which non-adrenegic, non-cholinergic nerve may be implicated such as priapism, obesity and hyperphazia. [0039]
  • The transition metal complexes of the present invention may be administered alone or in conjunction with another therapeutic agent, for example a NO synthase inhibitor such as an arginine derivative eg L-NMMA. Accordingly, a vet further aspect of the invention provides the use of a transition metal complex in conjunction with a NO synthase inhibitor in the manufacture of a medicament for the treatment of conditions caused by pathological NO production. [0040]
  • A further aspect of the present invention provides a transition metal complex as hereinbefore defined other than ferrioxamine B for use in medicine. [0041]
  • Whilst it may be possible for the transition metal complexes to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation. According to a further aspect, the present invention provides a pharmaceutical formulation comprising a transition metal complex as hereinbefore defined other than ferrioxamine B together with one or more pharmaceutically acceptable carriers therefor and optionally one or more other therapeutic ingredients. The carrier(s) must be “acceotable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. [0042]
  • The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. Most suitably, the formulation is suitable for oral or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy All methods include the step of bringing into association the transition metal complex (“active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation. [0043]
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste. [0044]
  • A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. [0045]
  • Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, saline, water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. [0046]
  • Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol. [0047]
  • Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia. [0048]
  • Preferred unit dosage formulations are those containing an effective dose, as hereinbelow recited, or an appropriate fraction thereof, of the active ingredient. [0049]
  • It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents. [0050]
  • The transition metal complexes of the invention may be administered orally or via injection at a dose of from 0.1 to 100 mg/kg per day, preferably 1 to 50 mg/kg per day. When the transition metal complexes are given by injection, this will normally be in the form of an intravenous bolus or by infusion, preferably the latter. The dose range for adult humans is generally from 70 mg to 2.5 g/day and preferably 150 mg to 2 g/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg. [0051]
  • The dose of the transition metal complexes vary according to the potency and the dose at which adverse pharmacological effects become evident. The man skilled in the art will take these factors into account when determining the dose of compound to be administered. [0052]
  • The activity of representative compounds of the present invention will now be described by way of example only:[0053]
    • EXAMPLE 1
  • Materials [0054]
  • Ferrioxamine B (deferoxamine-Fe(III) was synthesized by complexation reaction of Fe(III) salt (specifically FeNH[0055] 4(SO4)2.12H2O) with deferoxamine mesylate. Deferoxamine mesylate is N-[5-[3-[(5-amino-pentyl)hvdroxycarbamoyi]proplonoamido]pentyl]-3-[[5-(N-hydroxyactemido)-pentyl]carbamoyl]propionohydroxamic acid monomethanesulfonate(salt). The complex was then purified on a reverse phase HPLC. It was further characterized as a homogenous (single peak on TPLC) compound by 1H and 13C NMR, mass spectroscopy and elemental analysis. Deferoxamine mesylate was from Ciba-Geigy and ferric pyridoxal isonicotinoyl hydrazone and was obtained from Polysciences, Inc. (Warrington, Pa.).
  • Other complexes of the present invention are commercially available (e.g. from Aldrich, Milwaukee Wis., Fluka Chem. Corp., Ronkonkoma N.Y. and Pfaltz & Bauer Inc., Waterbury Conn.) or obtainable by methods known in the art. [0056]
    • EXAMPLE 2
  • Septic Shock in vivo Mode: [0057]
  • [0058] C. parvum/LPS-Induced Septic Shock in Mice
  • The Mouse Acute Septic-Shock model is used to test compounds for their capacity to ameliorate endotoxin-induced fulminate septic shock. [0059]
  • Male CD-I mice 25-30 g (Charles River) were injected i.v. with 100 μg killed [0060] C. parvum (Coparvax: Burroughs Weffcome. RTP. NC). Seven to ten days later the mice were injected i.v. with 20 μg. E. coli 026 B6 lipopolysaccharide in the presence of the analgesic butorphenol tartrate (150 μg per mouse) The drugs were dissolved or suspended in saline for intravenous or oral dosing 2 hours before and at the time of endotoxin injection. Mice were monitored over the next 7 hours and at 24-48 hours for survival. The results of the compounds tested are given in Table 1.
    TABLE 1
    %
    Survivors/ Survival
    Dose Total at at
    Compound Route mg/kg 48 hrs 48 hrs
    Contra. IV 0/8 0
    IP 0/8 0
    Ferrioxamine B IV 5 7/8 87.5
    Ferric pyridoxal isonicoanoyl IP 10 6/8 75
    hydrazone
    Tris(acetylacetonate) IP 1 5/8 62.5
    manganese III) IP 10 3/8 37.5
    Iron(III)citrate IV 1 5/8 62.5
    IV 10 4/8 50
    Diethylenetriaminepentaacetric IV 1 8/8 100
    acid iron(III) IV 10 4/8 50
    Ethylenediaminetetraacetic acid IV 1 0/8 0
    iron(III) IV 10 4/8 50
    Ferrous gluconate IV 1 3/8 37.5
    IV 10 6/8 75
    1,1′-ferrocenedimethanol IP 1 5/8 62.5
    IP 10 6/8 75
    Ethyl α-acetyl-4- IP 1 5/8 62.5
    (methoxycarbonyl)benzoylacetate, IP 10 3/8 37.5
    copper(II)
    Tris(ethylenediamine)nickel(II) IV 10 5/8 62.5
    sulphate IV 10 6/8 75
    Hexaaminenickel(II)chloride IP 1 4/8 50
    IP 10 4/8 50
    Bathopheneanthroline disulphonic IV 1 7/8 87.5
    acid IV 10 2/8 25

Claims (11)

1. The use of a transition metal complex, other than deferoxamine-manganese, hemin. diethyldithiocarbamic acid complexes or an iron hemoprotein, in the manufacture of a medicament for the treatment of septic shock.
2. The use according to claim 1 in which the transition metal is iron, copper, silver, zinc, manganese or nickel.
3. The use according to claim 1 or 2 in which the chelating agent is coordinated to the transition metal through one or more nitrogen atoms which may be contained in a polycyclic ring system or as a substituent in an alkylene chain, through an O− or S− anion; or by virtue of a pair of electrons.
4. The use according to claims 1, 2 or 3 in which the transition metal complex is
Ferrioxamine B
Ferric Pyridoxal Isonicotinoyl Hydrazone
Tris (acetylacetonato)manganese (III)
Iron (III) citrate
Diethylenetriaminepentaacetic acid Iron (III)
Ethylenediaminetetraacetic acid Iron (III)
Ferrous gluconate
1,1′-ferrocenedimethanol
Ethyl α-acetyl-4-(methoxycarbonyl)benzoylacetate, Copper (II)
Tris (ethylenediamine) nickel (II) sulfate
Hexaaminenickel (II) Chloride or
Bathopheneanthroline disulphonic acid.
5. The use of a transition metal complex, other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes or an iron hemoprotein, in the manufacture of a medicament for the treatment of conditions caused by pathological NO production
6. The use of a transition metal complex, other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes or an iron hemoprotein, in conjunction with a NO synthase inhibitor in the manufacture of a medicament for the treatment of conditions caused by pathological NO production.
7. A transition metal complex, other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes, an iron hemoprotein or ferrioxamine B, for use in medicine.
8. A pharmaceutical formulation comprising a transition metal complex other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes, an iron hemoprotein or ferrioxamine B, together with one or more pharmaceutically acceptable carriers therefor and optionally one or more other therapeutic ingredients.
9. A method of treating septic shock comprising administering to a mammal in need thereof an effective amount of a transition metal complex other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes or an iron hemoprotein.
10. A method of treating a condition caused by pathological NO production comprising administering to a mammal in need thereof an effective amount of a transition metal complex other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes or an iron hemoprotein.
11. A method of treating a condition caused by pathological NO production comprising administering to a mammal in need thereof an effective amount of a transition metal complex other than deferoxamine-manganese, hemin, diethyldithiocarbamic acid complexes or an iron hemoprotein, in conjunction with a NO synthase inhibitor.
US09/971,079 1993-05-06 2001-10-05 Treatment of septic shock Abandoned US20020091113A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/971,079 US20020091113A1 (en) 1993-05-06 2001-10-05 Treatment of septic shock

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB939309387A GB9309387D0 (en) 1993-05-06 1993-05-06 Nitric oxide scavengers
GB9309387.0 1993-05-06
US53792695A 1995-12-18 1995-12-18
US08/921,997 US6465511B1 (en) 1993-05-06 1997-08-27 Treatment of septic shock
US09/971,079 US20020091113A1 (en) 1993-05-06 2001-10-05 Treatment of septic shock

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/921,997 Continuation US6465511B1 (en) 1993-05-06 1997-08-27 Treatment of septic shock

Publications (1)

Publication Number Publication Date
US20020091113A1 true US20020091113A1 (en) 2002-07-11

Family

ID=10735068

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/921,997 Expired - Fee Related US6465511B1 (en) 1993-05-06 1997-08-27 Treatment of septic shock
US09/971,079 Abandoned US20020091113A1 (en) 1993-05-06 2001-10-05 Treatment of septic shock
US10/212,906 Expired - Fee Related US7022734B2 (en) 1993-05-06 2002-08-06 Treatment of septic shock

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/921,997 Expired - Fee Related US6465511B1 (en) 1993-05-06 1997-08-27 Treatment of septic shock

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/212,906 Expired - Fee Related US7022734B2 (en) 1993-05-06 2002-08-06 Treatment of septic shock

Country Status (9)

Country Link
US (3) US6465511B1 (en)
EP (1) EP0697864B1 (en)
JP (1) JP3844489B2 (en)
AT (1) ATE196083T1 (en)
AU (1) AU6682594A (en)
CA (1) CA2162154C (en)
DE (1) DE69425820T2 (en)
GB (1) GB9309387D0 (en)
WO (1) WO1994026263A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060204593A1 (en) * 2003-02-20 2006-09-14 Yusei Miyamoto Superoxide anion decomposing agent

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309387D0 (en) 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
PL317192A1 (en) * 1994-05-13 1997-03-17 Monsanto Co Methods of using pernitrite decomposition catalyst and their pharmaceutic compositions
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
AU776212B2 (en) * 1998-11-09 2004-09-02 Ira Jay Newman Ionic silver complex
AUPP784998A0 (en) * 1998-12-21 1999-01-21 Ghadiminejad, Iraj A low molecular weigh, non-proteinaceous compound that inhibits mitogen induced cytokine production
US20040101488A1 (en) * 2000-03-24 2004-05-27 Balaram Ghosh Method for the prevention of septic shock lethality using curcumin
FR2825920B1 (en) * 2001-06-15 2006-04-28 Oreal DESFERAL AS INHIBITOR OF NO-SYNTHASE AND USES
WO2003073997A2 (en) * 2002-03-01 2003-09-12 Luis Molina Treatment of septic shock
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
BG65787B1 (en) 2004-11-23 2009-11-30 Чавдар ВАСИЛЕВ Means of increasing the antigen-binding activity of immune globulin preparations
US8214310B2 (en) 2005-05-18 2012-07-03 International Business Machines Corporation Cross descriptor learning system, method and program product therefor
JP2013502407A (en) 2009-08-19 2013-01-24 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム Desferrioxamine metal complexes for treating immune related disorders
AU2013286876B2 (en) * 2012-07-03 2017-04-20 Jay Pravda Methods for treating, diagnosing and/or monitoring progression of oxo associated states
US9382151B2 (en) 2014-01-31 2016-07-05 Corning Incorporated Low expansion silica-titania articles with a Tzc gradient by compositional variation
US12053511B2 (en) 2016-11-30 2024-08-06 Board Or Regents, The University Of Texas System Cystatin C and Cystatin 9 to treat gut inflammation caused by thermal injury
WO2023086364A1 (en) * 2021-11-09 2023-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Composition containing 3-hydroxyanthranilic acid and compounds that alter iron homeostasis and method of its use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2891854A (en) * 1954-06-16 1959-06-23 Geigy Chem Corp Chelated iron compositions
US4451442A (en) 1982-06-21 1984-05-29 The Dow Chemical Company Removal of hydrogen sulfide from fluid streams with minimum production of solids
US5227405A (en) 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US5223538A (en) 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
DE3842143A1 (en) 1988-12-15 1990-06-21 Nitsche Dietrich USE OF TRANSFERRIN FOR ENDOTOXIN NEUTRALIZATION
US5296466A (en) 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
GB9309387D0 (en) 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060204593A1 (en) * 2003-02-20 2006-09-14 Yusei Miyamoto Superoxide anion decomposing agent
US7838043B2 (en) 2003-02-20 2010-11-23 Apt Co., Ltd Superoxide anion decomposing agent

Also Published As

Publication number Publication date
US6465511B1 (en) 2002-10-15
GB9309387D0 (en) 1993-06-16
JP3844489B2 (en) 2006-11-15
AU6682594A (en) 1994-12-12
CA2162154C (en) 2007-03-20
JPH08510449A (en) 1996-11-05
DE69425820T2 (en) 2001-03-22
ATE196083T1 (en) 2000-09-15
US7022734B2 (en) 2006-04-04
WO1994026263A2 (en) 1994-11-24
EP0697864A1 (en) 1996-02-28
EP0697864B1 (en) 2000-09-06
US20030008856A1 (en) 2003-01-09
DE69425820D1 (en) 2000-10-12
CA2162154A1 (en) 1994-11-24
WO1994026263A3 (en) 1995-01-05

Similar Documents

Publication Publication Date Title
US6465511B1 (en) Treatment of septic shock
JP3637418B2 (en) Nitric oxide-nucleophile adduct mixed ligand metal complexes useful as cardiovascular agents
EP1561463B1 (en) Benzamidoxime prodrugs as antipneumocystic agents
EP0501975B1 (en) Antihypertensive compositions and use thereof
EP0495776B1 (en) Stabilized nitric oxide-primary amine complexes useful as cardiovascular agents
JP2008525445A (en) Methods and compositions for enhancing iron absorption
JPH0811729B2 (en) A pharmaceutical composition comprising 1-hydroxypyrid-2-one, or a salt thereof, effective in reducing toxic levels of metals in the body of a patient.
US9441000B2 (en) Use of metallocene compounds for cancer treatment
US7135196B2 (en) Iron compositions
US2957806A (en) Process for raising blood serum iron levels and controlling anemia
US6380248B1 (en) Metal-thiols as immunomodulating agents
WO1996004909A1 (en) Use of quinone and hydroquinone derivatives for the teatment of cachexia
EP2833890A1 (en) Fe(iii)-pyrazine complex compounds for treatment and prophylaxis of iron-deficiency phenomena and iron-deficiency anaemia
EP1414830B1 (en) Tumour inhibiting lanthane compounds
WO2014154797A1 (en) Fe(iii) complexes for treatment and prophylaxis of iron deficiency symptoms and iron deficiency anaemias
DE3871879T2 (en) BRANCHED ALKYLESTERS OF 4-BIS (CHLOROALKYL) AMINOPHENYLALKYLCARBONIC ACIDS.
CN116710091A (en) Membrane iron transporter inhibitors for the treatment of myelodysplastic syndrome (MDS)
JP2004537599A (en) Cerium compounds having cytostatic activity
KR20050074450A (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
IE34325B1 (en) Treatment of shock
JP2003012519A (en) Colorectal cancer prevention / treatment agent containing ursodeoxycholic acid derivative as active ingredient

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION